Barbara Witek | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/barbara-witek/Barbara WitekHugo Blox Builder (https://hugoblox.com)en-usMon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngBarbara Witekhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/barbara-witek/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/Thu, 01 Sep 2016 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/